HPTN Happy Town Holdings Inc (CE)

Biologix Hair Inc. (OTCBB:BLGX) (OTCQB:BLGX) has appointed Dr. Guillermo A. Duran as Chief Medical Officer. Dr. Duran discovered Follicle Nutrient Deficiency Syndrome (FNDS) to be the causal effect of alopecia and went on to develop the preventive and regenerative treatment now known as the Biologix Hair Therapy System(TM).

Between mid-2004 and late 2011, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients by a select private consortium of medical clinicians located in South America. Participating patients either suffered with varying degrees of FNDS or were seeking preventive treatment to avoid onset of FNDS.

During those eight years, the clinicians subjectively estimated that healthy hair growth has been maintained in virtually 100% of those whose goal was to prevent the onset of Follicle Nutrient Deficiency Syndrome (FNDS) and resulting alopecia.

The clinicians further estimate that between 80 - 85% of their male patients and upwards of 90% of their female patients being treated for FNDS and seeking hair regeneration therapy have been able to regrow their lost hair.

Of the alopecia areata patients - both men and women - the rate of success has been observed to be nearly 100%.

Dr. Guillermo Duran is a medical doctor practicing in Barranquilla, Colombia. He graduated in 1988 from Juan N. Corpas University's medical school in Bogota and completed specialization in mesotherapy in 2000 at the Universite Victor Segalen Bordeaux 2 in France. Between 1994 and 2012 Dr. Duran continued his study of mesotherapy and esthetic medicine in Brazil.

From 1989 to 1990 Dr. Duran served as Executive Director of San Roque Hospital, as an Intensive Care Unit physician at the Ramon Gonzalez Valencia Hospital in Bucaramanga from 1991-92. He has been in private practice in mesotherapy and esthetic medicine since 1993. Dr. Guillermo Duran has been a guest speaker on the topic of trichology at several conferences, including in Brazil in 2008, Spain in 2011, and three times in Colombia from 2008-10.

Ron Holland, CEO of Biologix Hair Inc., commented, "I commend Dr. Guillermo Duran for his professionalism and high scientific and research standards. His discovery of FNDS and resultant formulation of what has become Biologix Revive promises to be a significant contribution to science and a benefit to millions of people around the world, if and when regulatory approval is granted. As we continue to take the necessary steps to prepare for application for regulatory agency approval, Dr. Duran's direct assistance as Chief Medical Officer will be especially helpful during this process."

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. (TM) (BHS), is focused on realizing the full market potential for its patent-pending hair loss formula - Biologix Revive - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.

BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.

Additionally, on May 11, 2012, Venable LLC, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.

Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System(TM), if and when FDA and other major market approvals are forthcoming.

As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists(TM) and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System(TM).

Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System(TM) is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.

To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.

Disclaimer

This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.

To view the images associated with this press release, please visit the following link:

http://media3.marketwire.com/docs/n319blgA.pdf

Contacts: Biologix Hair Inc. Corporate Communications Toll Free: +1 855.292.8585 OR +1 902.801.7920CorporateCommunications@BiologixHair.com www.BiologixHair.com